Liposome-Encapsulated Glucosamine: How Different Formulas Are Absorbed in Humans
Official title: Effect of Double Nutri® Liposomal Encapsulation Technology on Human Absorption of Glucosamine Supplements
Run by TCI Co., Ltd. · NCT07843342 · Data updated 2026-11-12
This study tests whether liposomal encapsulation and different ingredient ratios change how glucosamine in liquid form is absorbed in healthy adults.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 16 (estimated) |
| Sponsor | TCI Co., Ltd. Industry-sponsored |
| Locations | 1 site (Taipei) |
| Status | Recruiting |
| Started | October 21, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | January 29, 2027 |
| Registry record updated | September 28, 2026 |
| Trial ID | NCT07843342 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged 18 and older who can comply with all study procedures and provide informed consent.
✕Probably not a fit
Individuals with certain chronic GI conditions or those using glucosamine products recently may not experience additional benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, self-controlled crossover study in healthy adults to compare the blood levels of glucosamine after four different formulations. Participants receive four study sessions with at least seven days between sessions, consuming standardized meals around dosing. Blood samples are collected before dosing and at multiple time points up to 24 hours to assess glucosamine bioavailability, along with safety labs. The four interventions include high-emulsified liposomal glucosamine liquid, low-emulsified liposomal glucosamine liquid, glucosamine liquid without liposomal, and glucosamine tablet without liposomal. Safety monitoring includes basic metabolic and liver/kidney function tests, and consistency of meals is maintained across sessions.
Why it matters
Potential benefit: If successful, the findings could help identify which liposomal formulation offers better absorption for glucosamine supplements.
How similar studies have gone: Other studies in liposomal delivery have shown variable improvements in bioavailability; this study specifically tests four formulations in a crossover design.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged ≥18 years, regardless of sex, who are willing to sign the informed consent form and are able to fully comply with all study procedures. Exclusion Criteria: * Pregnant or breastfeeding women, or individuals who are unwilling to use a physical method of contraception during the study period, such as condoms or an intrauterine device. * Employees of TCI Co., Ltd. and their family members. * Individuals who have regularly taken any supplements or medications containing glucosamine or N-acetylglucosamine (N-acetyl-glucosamine) within 14 days prior to study initiation, defined as use for ≥7 consecutive days. * Individuals with a history of chronic gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), chronic diarrhea, Crohn's disease, celiac disease, bowel control problems/fecal incontinence, pancreatitis, peptic ulcer disease, colorectal cancer, short bowel syndrome, or ulcerative colitis; a history of epilepsy or seizures; liver or kidney disease; malignancy; endocrine disorders; psychiatric disorders; alcohol or substance abuse; or other significant organic diseases, as determined based on medical history. * Individuals with a history of gastrointestinal surgery, organ transplantation, or other major surgery. * Individuals who have experienced acute gastroenteritis within 2 weeks prior to study initiation. * Individuals with a history of allergy to any ingredient in the investigational products. The investigational products contain shrimp- and soy-derived ingredients. * Vegetarians, as the glucosamine used in this study is derived from shrimp.
Where it's running
-
TCI Co., Ltd
Taipei, Taiwan Recruiting
Study contacts
- Principal investigator: Tong-Lin Wu — TCI Co., Ltd.
- Study coordinator: Tong-Lin Wu
- Email: Tony.Wu@tci-bio.com
- Phone: +886 02-87977811
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SugarLock peanut skin extract before meals to see if it helps post-meal blood sugar in healthy adults
This study tests whether taking SugarLock peanut skin extract (and white kidney bean extract) before a meal can blunt or delay rises in blood glucose in healthy adults.
-
Liquid vitamin C and glutathione sachets for skin health
This test tries whether daily liquid vitamin C plus glutathione sachets improve skin appearance and reduce oxidative stress in healthy adults aged 18–65.
-
Avance eZZe drink for improving sleep in adults with insomnia
This trial tests whether drinking Avance eZZe with liposomal technology one hour before bed helps adults with insomnia sleep better over 28 days.
-
TCI604 probiotic to improve intestinal function
This trial will test whether the TCI604 probiotic can improve gut function and relieve constipation in adults with functional constipation.
-
Evaluating the effects of orange peel fermentation on reducing body fat in adults
This study is testing if eating fermented orange peel can help adults with overweight or fatty liver disease lose body fat.
-
Evaluating buckwheat husk extract for cardiovascular disease risk factors
This study tests if taking buckwheat husk extract daily can help people with certain blood pressure levels lower their risk factors for heart disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.